Abstract
Human cytomegalovirus (HCMV) causes a lifelong infection through establishment of latency. Although reactivation from latency can cause life-threatening disease, our molecular understanding of HCMV latency is incomplete. Here we use single cell RNA-seq analysis to characterize latency in monocytes and hematopoietic stem and progenitor cells (HSPCs). In monocytes, we identify host cell surface markers that enable enrichment of latent cells harboring higher viral transcript levels, which can reactivate more efficiently, and are characterized by reduced intrinsic immune response that is important for viral gene expression. Significantly, in latent HSPCs, viral transcripts could be detected only in monocyte progenitors and were also associated with reduced immune-response. Overall, our work indicates that regardless of the developmental stage in which HCMV infects, HCMV drives hematopoietic cells towards a weaker immune-responsive monocyte state and that this anergic-like state is crucial for the virus ability to express its transcripts and to eventually reactivate.
Original language | English |
---|---|
Article number | e52168 |
Journal | eLife |
Volume | 9 |
DOIs | |
State | Published - 22 Jan 2020 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2020, eLife Sciences Publications Ltd. All rights reserved.
Funding
We thank the members of the Stern-Ginossar lab for critical reading of the manuscript. We thank Eain A. Murphy for the TB40E-GFP virus strain. This research was supported by Infect-ERA (TANKACY) and the European Research Council starting grant (StG-2014-638142) to NS-G, and by the Cambridge NIHR BRC Cell Phenotyping Hub and a grant from the British Medical Research Council (Grant G0701279) to JS. NS-G is incumbent of the skirball career development chair in new scientist. B.S. and E.B. were supported by a Biomed-Connect Grant from the University of Sydney.
Funders | Funder number |
---|---|
British Medical Research Council | |
Cambridge NIHR BRC | |
Horizon 2020 Framework Programme | 638142 |
Medical Research Council | G0701279 |
European Commission | StG-2014-638142 |
University of Sydney | |
NIHR Cambridge Biomedical Research Centre |